Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Perspectives
Our Leadership
Ethics & Compliance
Investors
Fresh thinking grounded in reality across the full lifecycle
Tackle the new realities of drug development and commercialization with Quintiles’ broad industry expertise. The result: Strategies that drive success.
Strategic Portfolio Management
How can good portfolio planning help to ensure commercial success of a product? Read white paper
The Art of Compliance
Turning regulatory compliance into sustainable business advantage. Read white paper
Oncology Drug Development and Value-Based Medicine
The growing voice of stakeholders, from patients to payers, is changing the path of drug development. Read white paper
With access to all Quintiles’ experts, our integrated consulting teams bring you implementatble, sustainable solutions across the lifecycle.
A seismic power shift from providers to payers makes proving value an ongoing challenge. Learn more
Heightened regulatory scrutiny can turn compliance into a competitive edge. Find out how
As market pressures mount, process efficiencies can make the difference between success and failure. Read more
Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research Read more
Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock Read more
Quintiles Announces Pricing of Initial Public Offering Read more
Harnessing the Power of the Digital Patient White Paper Read more
Tomorrow’s Path to Improved Early-Phase Oncology Drug Development Read more
Strategic Portfolio Management & New Influencers in R&D Decision-Making Read more